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Abstract
Background: The benefit of self-monitoring of blood glucose (SMBG) in people with type 2 diabetes on diet or
oral agents other than sulphonylureas remains uncertain. Trials of interventions incorporating education about self-
monitoring of blood glucose have reported mixed results. A recent systematic review concluded that SMBG was
not cost-effective. However, what was unclear was whether a cheaper method of self-monitoring (such as urine
glucose monitoring) could produce comparable benefit and patient acceptability for less cost.
Methods/Design: The DESMOND SMBG trial is comparing two monitoring strategies (blood glucose monitoring
and urine testing) over 18 months when incorporated into a comprehensive self-management structured
education programme. It is a multi-site cluster randomised controlled trial, conducted across 8 sites (7 primary care
trusts) in England, UK involving individuals with newly diagnosed Type 2 diabetes.
The trial has 80% power to demonstrate equivalence in mean HbA1c (the primary end-point) at 18 months of
within ± 0.5% assuming 20% drop out and 20% non-consent. Secondary end-points include blood pressure, lipids,
body weight and psychosocial measures as well as a qualitative sub-study.
Practices were randomised to one of two arms: participants attend a DESMOND programme incorporating a
module on self-monitoring of either urine or blood glucose. The programme is delivered by accredited educators
who received specific training about equipoise. Biomedical data are collected and psychosocial scales completed at
baseline, and 6, 12, and 18 months post programme. Qualitative research with participants and educators will
explore views and experiences of the trial and preferences for methods of monitoring.
Discussion: The DESMOND SMBG trial is designed to provide evidence to inform the debate about the value of
self-monitoring of blood glucose in people with newly diagnosed type 2 diabetes. Strengths include a setting in
primary care, a cluster design, a health economic analysis, a comparison of different methods of monitoring while
controlling for other components of training within the context of a quality assured structured education
programme and a qualitative sub-study.
Trial registration: ISRCTN: ISRCTN95696668.
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Background
The prevalence of diabetes is increasing and it is esti-
mated around 7.8% of the worldwide adult population
will be affected by 2030 (up to 95% of whom will have
type 2 diabetes (T2DM)) [1]. This growing burden on
individuals, their families and healthcare systems empha-
sises the importance of developing effective, cost-effective
and acceptable methods to manage this condition. Tight
glycaemic control in people with diabetes can reduce a
wide range of tissue complications including microvascu-
lar and large vessel disease [2]. Developing interventions
that help people to self-manage their condition is vital.
One component of diabetes self-management, self moni-
toring of blood glucose (SMBG) is considered by many to
be essential but its precise role in the management of
T2DM continues to evoke considerable controversy.
SMBG, hailed as one of the most important develop-
ments in diabetes care since the discovery of insulin, costs
the UK National Health Service millions of pounds per
year and the cost is rising [3]. For many with insulin trea-
ted diabetes and their families, the ability to measure
blood glucose immediately is one of the essential manage-
ment tools, enabling them to confirm suspected hypogly-
caemic episodes or high glucose values rapidly and to take
corrective action. However, over 30 years after its intro-
duction, the degree to which SMBG contributes to
improved metabolic control in non-insulin treated or
newly diagnosed T2DM remains equivocal [4,5].
Structured education, which teaches the skills neces-
sary to use information from SMBG to adjust insulin
dose, can lead to sustained improvements in glycaemic
control in individuals with Type 1 diabetes (T1DM), [6]
although the contribution of SMBG within a complex
intervention is unclear. Significant numbers of people
with T1DM use SMBG to reflect on blood glucose levels,
adjust their insulin dose and maintain optimum glycae-
mic levels. However, our clinical impression is that many
individuals with T1DM religiously record the results but
do nothing with them. Nevertheless, both patients and
professionals would agree that SMBG technology should
be available to everyone who uses insulin if only to detect
and treat hypoglycaemia [7,8].
The situation is much more uncertain for individuals
with T2DM, particularly those managing their condition
with lifestyle adjustments or using oral agents other than
sulphonylureas. This uncertainty is reflected in the wide
variation in the use of SMBG in different parts of the UK,
[9] but even in areas where SMBG is used less often, the
estimated costs are considerable, amounting to hundreds
of thousands of pounds in an average primary care trust.
It has been argued that providing such technology to
those on tablets or diet is a waste of time and money
since there is little an individual can do with the result
[10]. Others believe strongly that the information pro-
vided by SMBG is a powerful motivating factor, [11]
encouraging self-management by enabling people with
T2DM to measure directly the effect of different actions,
such as the effect of eating on post-prandial glucose or
the glucose lowering effect of exercise. Previous studies
have attempted to assess the contribution of SMBG to
improved metabolic control in this group. Most, [12,13]
but not all, [14] observational studies have shown that
even in those managing their T2DM using diet alone,
increased frequency of SMBG is associated with better
outcomes including lowered glycated haemoglobin
(HbA1c) and less mortality. This has been used to advo-
cate SMBG for all those with T2DM [15]. However, these
results may merely indicate that those who are highly
motivated (reflected in the take-up of SMBG technology)
are likely to do well in the long term.
Trials of interventions incorporating education about
SMBG have reported mixed results. The DIGEM study
reported no evidence of an effect of SMBG (with or with-
out support from trained practice nurses in the interpreta-
tion and application of results) [16]. However, limitations
included potential contamination due to lack of cluster-
randomisation, a drop in adherence to SMBG over the
study period, [17] and exclusion of people with prior
experience of SMBG. Similarly, the ESMON study
reported no evidence of an effect of structured education
with or without additional education on self-monitoring
[18]. Both studies reported a net adverse effect on anxiety/
depression, suggesting that SMBG increased worry and
depressed mood.
Uncertainty in this field prompted NHS Diabetes to
commission a multi-disciplinary working group to under-
take a systematic review and meta-analysis of relevant
trials and studies [4,5]. This reported a reduction in
HbA1c of 0.21% from “simple” SMBG over no SMBG; a
reduction of 0.52% from “enhanced” SMBG (with educa-
tion, feedback, etc.) over no SMBG; and no difference
between SMBG and urine testing [5]. In regard to cost-
effectiveness, most studies did not allow for the poten-
tially negative impact of SMBG on patient reported out-
comes [5]. Those studies funded by manufacturers
tended to be more favourable [5]. The estimated cost of
SMBG in England is around £30 million a year. Studies
that applied the most robust analyses, taking into account
all costs, gains and disutilities, concluded that SMBG was
not cost-effective [5]. However, what was unclear was
whether a cheaper method of self-monitoring (such as
urine glucose monitoring) could produce comparable
benefit and patient acceptability for less cost.
Patient acceptability of the means of monitoring may
be particularly important in sustaining effective self-
management, thus the review included qualitative studies
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that had addressed this [5]. While SMBG was shown to
have the potential to motivate and improve T2DM self-
management in some people, it could also cause adverse
psychological effects including depression and self-chas-
tisement [5]. A failure to educate patients in interpreta-
tion and application of self-monitoring results was a
consistent finding, along with a reported lack of interest
in patients’ self monitoring results from healthcare pro-
fessionals (HCPs) and a frequent failure to act on the
results [5]. People with newly diagnosed T2DM generally
preferred blood to urine monitoring, finding it more
hygienic and accurate though it should be noted that in
the study quoted participants had not received structured
education or consistent advice on what do to with the
results [19]. Acceptability of method is likely to be influ-
enced by perceptions of disease severity; necessity for
self-management; accuracy and effectiveness of monitor-
ing method; usefulness of results; convenience and dis-
ruption to daily life. When an educational element is
involved, perceptions and experiences will be influenced
by additional factors, [20] particularly the attitude of the
HCPs delivering the education as well as those of the pri-
mary care team.
The review did not include one particular structured
approach to monitoring, the Structured Testing Pro-
gram (STeP) cluster-randomised trial (published
recently) [21]. STeP reported a significantly greater
reduction in mean HbA1c levels in people with T2DM
allocated to ‘structured’ SMBG (using a tool to collect
7-point glucose profiles over 3 days) compared with
those allocated to enhanced usual care including
SMBG (-0.3% difference, and -0.5% difference per pro-
tocol analysis) [21]. Unlike DIGEM and ESMON, the
STeP study demonstrated a significant reduction in
depressed mood among those using the ‘structured’
SMBG in those with clinically significant depressed
mood at baseline [21]. None of the interventions in the
studies cited have involved group education and nor
were they embedded in routine provision of education
to those with newly diagnosed T2DM. Furthermore
reports of these studies provide little information
about the education involved in their intervention, and
the training of educators.
In the UK the National Institute for Health and Clinical
Excellence and the Diabetes National Service Framework
now recommend that people with T2DM have access to
structured education, [22,23] with an expectation that pri-
mary care trusts (PCTs) provide high quality courses for
those newly diagnosed. It is important to establish the
most appropriate and cost-effective form of self-monitor-
ing for this group of patients. The aim of the DESMOND
(Diabetes Education and Self Management for ongoing
and Newly Diagnosed) SMBG Trial is to do this while
controlling for the type and degree of education in self-
management.
Study objectives and outcome measures
The primary objective is to ascertain whether there are
equivalent changes in HbA1c (primary outcome mea-
sure) in people with newly diagnosed T2DM allocated to
either a urine or a blood glucose monitoring strategy
over 18 months when incorporated as an integral part of
a comprehensive self-management structured education
programme (DESMOND).
The secondary objectives include: comparison of the two
strategies on the secondary outcome measures over 18
months, including biomedical measures (systolic and dia-
stolic blood pressure, lipid profile, body weight and waist
circumference) and psychological measures (well being,
anxiety, depression, treatment satisfaction and perceptions
about diabetes) (for further details see Table 1). A qualita-
tive sub-study will explore participant views about accept-
ability of, and preference for, the two self-monitoring
methods included. An assessment of cost effectiveness will
be conducted.
Presentation of the hypothesis
Our null hypothesis is that use of SMBG rather than urine
monitoring in the context of delivering the DESMOND
intervention will not be equivalent in terms of improving
and sustaining glycaemic control over 18 months.
Testing the hypothesis
We will be measuring the equivalence of SMBG (and its
cost-effectiveness) over a clinically relevant period of fol-
low-up while controlling for the other components of a
complex intervention, in particular, the educational pro-
gramme itself and feedback of glucose levels from another
form of monitoring.
Implications of the hypothesis
The DESMOND SMBG trial will provide additional evi-
dence to inform the debate around the value of SMBG
for people with T2DM not using insulin or at risk of
hypoglycaemia. In particular it will allow us to assess
whether SMBG is equivalent to urine monitoring in peo-
ple with newly diagnosed T2DM who are undertaking a
quality assured structured education course delivered in
primary care.
If the null hypothesis is not rejected, then SMBG will
not be recommended for people with newly diagnosed
T2DM. However, if the null hypothesis is rejected, and
the results demonstrate that SMBG is equivalent to urine
monitoring in terms improving and sustaining glycaemic
control over 18 months, then this will be used as evi-
dence to recommend SMBG for people with newly
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diagnosed T2DM who are undertaking the DESMOND
intervention.
Methods/Design
The study is an 18 month multi-site cluster randomised
controlled trial conducted in 8 sites in 7 PCTs in Eng-
land, and managed by a central DESMOND Research
Office. Ethical approval was received from Cambridge-
shire Research Ethics Committee (07/H0304/129) and
local research governance approval from participating
PCTs.
Practices are randomised to one of two arms: 1) Parti-
cipants attend a DESMOND structured education pro-
gramme which includes a module on self-monitoring of
blood glucose; and 2) Participants attend a DESMOND
structured education programme which includes a mod-
ule on self-monitoring of urine glucose.
Setting and recruitment of PCTs
The study is being conducted in primary care in a cross-
section of settings ranging from inner city to rural PCTs.
Two criteria were used when approaching PCTs about
participating in the study. First, they were required to have
a team of accredited DESMOND educators who were
interested and willing to participate. Second, PCTs needed
to be willing to support the prescription requirements of
the study. PCTs vary in their policy on the prescription of
blood glucose monitoring strips for people with non-insu-
lin treated T2DM, which can be a contentious issue due
to the prescribing costs involved. Practices are refunded
the cost of prescriptions for test strips to prevent the cost
being a barrier to self-monitoring within the trial.
Randomisation of practices
The study is cluster-randomised, with all enrolled partici-
pants in one practice randomised to one arm of the trial
in order to avoid potential ‘contamination’ from partici-
pants randomised to different arms. Randomisation was
carried out independently at the University of Leicester,
after stratification for practice setting and list size. Two
randomisation plans were computed, one for small and
one for large lists sizes. aPractices agreed to participate in
the study before being randomised. Practices were not
informed of their randomisation when recruited, but
become aware of it during the study as participants
attend the practice for clinical support and repeat pre-
scriptions for monitoring resources.
Patient eligibility criteria
People with newly diagnosed T2DM were referred by
their practice within 12 weeks of diagnosis. They were
excluded if they were under 18 years, were taking insulin,
had severe and enduring mental health problems, were
not primarily responsible for their own care, were unable
or unwilling to participate in a group programme (for
example, housebound or unable to communicate in Eng-
lish), or were participating in another research study.
They were not eligible if they had already started SMBG,
Table 1 Biomedical and questionnaire measures used and time points in the trial
Baseline 6 months 12 months 18 months
Biomedical measures
HbA1c (mmol/mol) ✓ ✓ ✓ ✓
Systolic blood pressure (mmHg) ✓ ✓ ✓ ✓
Diastolic blood pressure (mmHg) ✓ ✓ ✓ ✓
Total cholesterol (mmol/l) ✓ ✓
HDL cholesterol (mmol/l) ✓ ✓
LDL cholesterol (mmol/l) ✓ ✓
Triglycerides (mmol/l) ✓ ✓
Weight (kg) ✓ ✓ ✓ ✓
Waist circumference (cm) ✓ ✓ ✓ ✓
Questionnaire measures
The Well-being Questionnaire 28 (W-BQ28) [24,25] ✓ ✓ ✓ ✓
Brief Illness Perceptions Questionnaire (BIPQ) - diabetes version [26] ✓ ✓ ✓ ✓
Short-Form 36 (SF-36) [27] ✓ ✓
Summary of Diabetes Self-Care Activities (SDSCA). [28] ✓ ✓ ✓
Euro-Qol (EQ-5D) [29] ✓ ✓ ✓ ✓
Confidence in Diabetes Self-care (CIDS) [30] ✓ ✓ ✓
Diabetes Treatment Satisfaction questionnaire (DTSQ) [31] ✓ ✓ ✓ ✓
Beliefs about self monitoring* ✓ ✓ ✓
*Set of questions on beliefs and attitudes towards self monitoring. Questions were developed for the DiGEM study and have been adapted by Dr Jane Speight
with kind permission from Dr Andrew Farmer
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(unless this involved informal ‘trial and error’ without
instruction from a HCP and they were willing to be ran-
domised to either type of monitoring). Participants were
required to attend a DESMOND programme within
6 months of diagnosis.
Referral and recruitment of participants
Practice nurses referred people who were newly diagnosed
with T2DM and interested in participating in the study to
the local DESMOND team. A member of the local DES-
MOND team then contacted each individual referral to
confirm eligibility and check readiness to participate; if
willing the individual was booked to attend an appropriate
DESMOND programme. Practice nurses and DESMOND
co-ordinators were instructed not to tell individuals which
type of course they would be attending.
Collection of baseline and follow-up data
Participants were sent a questionnaire booklet containing
a set of questionnaire tools (Table 1) which they were
asked to complete and bring to the programme. Upon
attendance, prior to the programme commencing, writ-
ten informed consent was taken by the educators. Partici-
pants were informed which arm of the study they were
allocated to after informed consent was established and
the programme started.
Biomedical data collected at diagnosis by the primary
care team (see Table 1) were sent to the local DESMOND
team. These constituted baseline data for participants who
consented to join the study.
Follow-up data are collected by practice nurses at 6, 12
and 18 months post-programme. Two weeks before each
follow-up date, the DESMOND Research Office sends par-
ticipants a letter asking them to complete and return an
enclosed questionnaire. The letter also asks them to con-
tact their general practice and arrange an appointment for
the study measures to be made. The practice is sent a
letter at the same time, asking them to collect the informa-
tion and return it to the research office. A reminder letter
and questionnaire are sent to the participant after four
weeks if the questionnaire has not been returned; practices
who do not return follow-up data are contacted and
prompted for the information. If, for some reason, data
are not collected at a follow-up point, the participant is
approached at the subsequent follow-up, unless they have
been formally withdrawn from the trial.
Study intervention
The study intervention is the DESMOND Newly Diag-
nosed structured education programme with specific ses-
sions on SMBG, compared with the same programme
with specific sessions on self-monitoring of urine glucose
[32]. The standard programme involves 6 h of contact
time, facilitated by two trained HCPs. The content of the
curriculum is designed for people attending within 12
weeks of diagnosis and focuses on cardiovascular risk fac-
tors and associated lifestyle factors, such as food choices
and physical activity. The broad content of the curricu-
lum has been reported elsewhere [33]. The HCPs attend
a formal training programme in order to be accredited as
DESMOND Educators [34]. A quality development path-
way and specifically developed and tested quality assur-
ance tools are used to ensure consistency of delivery.
The standard DESMOND Newly Diagnosed programme
includes a 20 min session on self-monitoring which covers
the difference between short term and long term monitor-
ing of blood glucose, without detailed coverage of the dif-
ferent methods, and forms a relatively small part of the
programme. However, for the purpose of the trial, the ses-
sion on self monitoring has been extended in length and
content. The development, piloting and content of the
self-monitoring sessions for the trial and the training of
the DESMOND educators are described below.
Development and piloting of self-monitoring sessions
Experienced DESMOND trainers developed and piloted
the new self-monitoring sessions using an iterative cycle.
Six educators from 3 PCTs were then trained in delivery
of the sessions before delivering it incorporated into the
DESMOND programme to patients in their area. Subse-
quently the educators provided feedback which led to revi-
sion of the sessions and resources.
The 6-h DESMOND structured education programme is
underpinned by a philosophy and learning theories that
promote adult learning through interactive step-wise
processes, which increase self-efficacy to promote self-
management [33]. Therefore, the newly developed moni-
toring sessions needed to reflect these principles.
The content of the self-monitoring sessions is sum-
marised in Table 2. It was delivered in two separate ses-
sions, totalling 100 min in length. They were embedded
within the DESMOND education programme, which for
the purpose of this study is delivered in two sessions, one
to two weeks apart. Resources were developed for use
within the sessions to enhance participant interaction
and self confidence, support a reflective approach to self-
monitoring, and identify self management changes in
relation to results. The approach to self-monitoring is
not directive and regimented but promotes the practice
of self-monitoring as a tool to support decision making
in regard to lifestyle changes and medication. Participants
were encouraged to decide when and how often to moni-
tor, how to interpret the results and to explore options
for change. Although they were allocated randomly to
either the blood or urine method of monitoring, they are
able to swap methods or to stop monitoring if they
choose. Participants were asked to report any change in
method on the 6, 12 or 18 month questionnaire.
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Methods of self-monitoring
The first session involves experiential learning with the
method of self-monitoring allocated. Participants in the
blood monitoring arm were taught how to use the Ascen-
sia Contour meter; those in the urine monitoring arm
were taught how to use Diastix urine strips and all parti-
cipants were provided with two pots of test strips. In the
second session they were encouraged to discuss their
monitoring experiences and challenges. During the study
participants obtain further supplies of strips by repeat
prescription from their practice. The majority of study
participants are exempt from prescription charges, but
there is a procedure in place to enable those who are not
exempt to reclaim the cost.
Training of educators
To maximise fidelity of the intervention, educators were
trained to deliver these expanded monitoring sessions.
The training consisted of an initial training course (1 1/2
days) which included modelling of delivery of the self-
monitoring sessions by the trainers. A second training
course (1 day) halfway through the study provided an
update and the opportunity to deliver the sessions to their
peers and receive feedback.
The training included a session designed specifically to:
1) inform educators about the concept of equipoise -
agreement in the scientific community that there is genu-
ine uncertainty whether one treatment is more beneficial
than another, [35] and 2) raise educators’ awareness of
their own views about the two monitoring methods (i.e.
the two arms of the trial). This included reflection on
how their personal beliefs, attitudes and behaviours
might impact on their delivery of the sessions and in turn
the outcome of the study. It is important to note that the
training was not designed to achieve a position where
every educator was considered to be in individual equi-
poise regarding self-monitoring. Rather, it enabled educa-
tors to explore and recognise their personal beliefs and
how these beliefs may impact on their delivery of the
intervention, and to learn behaviours that would prevent
this type of impact.
The educators’ beliefs about self-monitoring were
assessed using a bidirectional linear scale [36]. The scale
consisted of a 5 m ribbon placed on the floor with the
ends labelled ‘blood monitoring’ and ‘urine monitoring’
and the centre labelled ‘neutral’. The educators were asked
to position themselves on the line in a place that reflected
their views and beliefs about the two methods of monitor-
ing. Initially the task was done individually without other
educators observing; the task was then used in a group set-
ting to create an opportunity for discussion of the concept
of equipoise and the potential impact of beliefs on deliver-
ing the intervention.
During the trial, DESMOND trainers observed the edu-
cators delivering the sessions in order to ensure that deliv-
ery reflected the curriculum and was not biased with
regards to the method of monitoring, and to provide feed-
back and support to the educators.
Involvement of practice nurses
Practice nurses based in participating practices are
involved in providing care and support for participants
over the 18 months of the study. They also provide
repeat prescriptions for monitoring strips. A total of 75
practices are taking part in the study and it was therefore
not possible to provide extensive training to the practice
nurses involved. Each nurse received a one hour visit
from a member of the research team which covered the
study’s standard operating procedures for the collection
of data and the importance of being impartial and neutral
Table 2 Contents of sessions on self-monitoring included in DESMOND programme in trial
Session 1 Monitoring and measuring blood glucose levels (20 mins)
• Long term blood glucose control using HbA1c and recommended targets
• How measurement of long term glucose control differs from self monitoring
• Introduction to Health Profile
Methods of self monitoring (20 mins) *
• Purpose of self monitoring and how to use the information
• How and when to monitor blood/urine
• Target levels for blood/urine monitoring
Purpose of self monitoring (20 mins)
• Purpose of self monitoring and how each individual can use the information he/she gathers
Session 2 (1 to 2 weeks later) Monitoring, feedback and action planning (40 mins)
• How to interpret test results, identify personal targets and act on them
• Key messages related to self-monitoring
• Importance of confidence score
• How to action plan for self monitoring
* Content varied depending on whether the session was covering urine or blood monitoring
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when they discussed monitoring methods with the parti-
cipant. They were encouraged to follow the approach
used by DESMOND educators to help the participant
self-manage their diabetes.
Analysis
Power calculations and sample size
The aim is to show equivalence in mean HbA1c at 18
months of within ± 0.5%. Assuming a standard deviation
(SD) at 18 months of 1.5%, [37] the sample size required
without allowing for clustering for 80% power at 5% signif-
icance is 142 per arm. With an intra-cluster correlation of
0.05, [38] and an expected mean cluster size of 5, adjust-
ment for clustering brings the number required to 170 per
arm. Assuming 20% drop out and 20% non-consent, the
numbers required are 266 referrals and 213 consents per
arm.
Statistical analysis
There will be double entry of all data and discrepant
values will be investigated. Results will be reported accord-
ing to CONSORT guidelines for cluster randomised trials
and statistical analysis carried out on an intention-to-treat
basis. Missing outcomes will not be replaced and an aver-
age over-time of continuous outcomes will be derived.
This procedure will measure the cumulative effect of the
treatment and have the maximum number of participants.
Continuous variables will be analysed using a linear model
adjusting for clustering using generalised estimating equa-
tions, and adjusting for baseline values.
Economic evaluation
The evaluation will be undertaken from the NHS perspec-
tive. The health service use costs of the two strategies will
be calculated at 18 months in both groups. Costs incurred
between 12 and 18 months will be discounted at 3.5%, in
line with NICE guidelines. The mean cost of the two
groups over 18 months will be compared using non-para-
metric tests. Results will be reported with 95% confidence
intervals and uncertainty will be examined using sensitivity
analysis.
An incremental cost-effectiveness ratio will not be calcu-
lated over the 18 months of the intervention as this length
of follow-up does not capture all relevant costs and out-
comes. Consequently, without the use of modelling, a
cost-effectiveness analysis could be misleading. The need
or otherwise for cost-effectiveness modelling will depend
on there being economically important clinically signifi-
cant differences in glycaemic control, as determined by
the likely impact on and hence, long-term effects on mor-
bidity and mortality. Whether any differences in glycaemic
control are important will be informed by reviewing the
cost-effectiveness of other interventions that have been
evaluated using lifetime models. If such differences do
exist, the modelling of the longer-term effects to assess the
incremental cost per quality adjusted life-year will be
conducted.
Qualitative sub-studies
In order to investigate the acceptability of the two moni-
toring methods, qualitative semi-structured interviews are
being conducted with a small sample of participants
including a similar number of those allocated to each
monitoring method in the trial. The focus of this is to
explore participants’ views and experiences of using the
allocated monitoring method (and the other method if
they swapped) as part of their self-management of T2DM.
Interviews are conducted approximately one year after
attending the DESMOND SMBG programme.
In addition, focus groups and qualitative interviews are
being conducted with a sample of the DESMOND educa-
tors involved in delivering the DESMOND SMBG inter-
vention at different points throughout the trial period. The
purpose of this is to explore educators’ views and experi-
ences of the trial including: the training and their delivery
of the intervention, their views and preferences with
regards to the two monitoring methods, and their reflec-
tions on delivering both arms of a trial while potentially
not being in individual equipoise.
Discussion
The DESMOND SMBG trial has been designed to provide
additional evidence to inform the debate around the value
of SMBG for people with Type 2 diabetes (T2DM) not
using insulin or at risk of hypoglycaemia. Its particular
strength is that it will allow us to assess the additional con-
tribution of SMBG in people with newly diagnosed T2DM
who are undertaking a quality assured structured educa-
tion course delivered in primary care. Our hypothesis is
that use of SMBG rather than urine monitoring in the
context of delivering the DESMOND intervention will
provide no added benefit in improving and sustaining gly-
caemic control over 18 months. Thus, we will be measur-
ing any added benefit of SMBG (and its cost-effectiveness)
over a clinically relevant period of follow-up while control-
ling for the other components of a complex intervention,
in particular, the educational programme itself and feed-
back of glucose levels from another form of monitoring.
We will also compare the effect of the two self-moni-
toring methods on secondary outcome measures, includ-
ing biomedical (systolic and diastolic blood pressure,
lipid profile, body weight and waist circumference), and
psychological (generic and disease specific well being,
treatment satisfaction and perceptions about diabetes)
measures. We will explore the views of participants con-
cerning their experience of and preference for the two
methods, and measure which self-monitoring strategy
participants adopt over the subsequent 18 months. We
will calculate the cost effectiveness of both methods.
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Attitudes to self-monitoring are influenced by people’s
experience of the real world, as is the success or otherwise
of their self-monitoring strategies. While our study is care-
fully planned and monitored, by virtue of the fact that it is
embedded in the real world, it is in essence a pragmatic
trial. The incorporation of questionnaires investigating
psychosocial aspects and impact of self-monitoring will
provide an important contribution to questions about
acceptability of the methods; the findings of which will
help illuminate the results of the main trial. The question-
naires will both record and monitor changes in self-moni-
toring strategies among the participants and the qualitative
sub-study will seek a greater understanding of participant
attitudes and preferences in respect of self-monitoring.
Since the DESMOND education programme has been
shown to be active in changing illness beliefs, [32] we will
also be examining the benefit of SMBG within an educa-
tion programme which has been set up to enable partici-
pants to exploit the benefits of feedback from direct
measurement of their glucose levels. Finally to prevent
potential contamination from attitudes of practice clinical
staff we have undertaken cluster randomisation at the level
of the practice.
Our trial is also exploring the effect of specific attention
to the potential influence of educators’ attitudes upon
intervention delivery through targeted training and
through assessment of attitudes and preferences. The
training highlighted issues of potential bias in intervention
delivery by specifically raising awareness of equipoise and
by formally assessing educators’ delivery of the interven-
tion in both arms of the trial. A qualitative sub-study with
the educators will enable us to investigate their attitudes
towards and experiences of both the training they received
and delivery of the intervention(s).
Endnote
aRandomisation was computed using the online resource
at http://www.tufts.edu/~gdallal/randomize.htm.
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